Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Activation of Collimators Irradiated With Clinical Proton Beams and Development of a Semiempirical Model for Activity Calculation

Carnicer, Adela1; Candela-Juan, Cristian2; Nirrengarten, Manon1; Blideanu, Valentin3; Mazal, Alejandro2; Hérault, Joël1; Delacroix, Sabine2

doi: 10.1097/HP.0000000000001082
PAPERS
Buy

Patient-specific collimators used in proton therapy are activated after use. The aim of this work is to assess the residual activity in brass collimators considering clinical beams, so far studied only for monoenergetic beams, and to develop a model to calculate the activity. Eight brass collimators irradiated with different clinical and monoenergetic beams were included in the study. The collimators were analyzed with gamma spectrometry in the framework of three independent studies carried out at the two French proton therapy sites. Using FLUKA (a fully integrated particle physics Monte Carlo simulation package), simulations were performed to determine radionuclides and activities for all the collimators. The semiempirical model was built using data calculated with FLUKA for a range of clinical beams (different maximum proton energies, modulations, and doses). It was found that there was global coherence in experimental results from different studies. The relevant radionuclides at 1 mo postirradiation were 57Co, 58Co, and 65Zn, and additionally, 54Mn, 56Co, and 60Co for high-energy beams. For nondegraded monoenergetic beams, differences between FLUKA and spectrometry were within those reported in reference benchmark studies (±30%). Due to the use of perfect monochromatic sources in the FLUKA model, FLUKA results systematically underestimated experimental activities for clinical beams, especially for 65Zn, depending on the beam energy spread (modulation, degradation, beam line characteristics). To account for the energy spread, correction factors were derived for the semiempirical model. The model is applicable to the most relevant radionuclides and total amounts. Secondary neutrons have a negligible contribution to the activity during treatment with respect to proton activation.

1Centre Antoine Lacassagne (CAL), Nice, France

2Centre de Protonthérapie d’Orsay Institut Curie (ICPO), Orsay, France

3Commissariat à l’énergie atomique (CEA-Saclay), Gif-sur-Yvette, France.

The authors declare no conflicts of interest.

For correspondence contact Adela Carnicer, Centre Antoine Lacassagne, 227 avenue de la Lanterne, 06200 Nice, France, or email at adela.carnicer@gmail.com.

(Manuscript accepted 16 January 2019)

Online date: June 7, 2019

© 2019 by the Health Physics Society